A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis

NCT07502222 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate-to-Severe Atopic Dermatitis

Interventions

BIOLOGICAL: AK139 and placebo
BIOLOGICAL: AK139
BIOLOGICAL: AK139 and placebo
BIOLOGICAL: AK139
BIOLOGICAL: AK139 and placebo
BIOLOGICAL: AK139 and placebo
BIOLOGICAL: Placebo

Sponsor

Akeso